In this study, we investigated whether a combination of two novel in silico-designed compounds, namely, ITH-47 (BRD4 inhibitor) and ESE-15-ol (an antimitotic agent), would synergistically inhibit the growth of breast cancer cells, MCF-7 and MDA-MB-231 (Figure 1). The gene discussed is BRD4; the disease is breast cancer.